Suppr超能文献

心脏移植患者接受肾脏替代治疗后的生存情况。

Patient survival with renal replacement therapy in heart transplantation patients.

作者信息

Bernardini J, Piraino B, Kormos R L

机构信息

Department of Medicine, University of Pittsburgh School of Medicine, Pennsylvania, USA.

出版信息

ASAIO J. 1998 Sep-Oct;44(5):M546-8. doi: 10.1097/00002480-199809000-00046.

Abstract

Long-term survivors of cardiac transplantation are at risk for nephrotoxicity caused by many years of immunosuppressive therapy with cyclosporine or tacrolimus. We report on 12 patients who received heart transplants at the University of Pittsburgh, with subsequent development of end-stage renal disease (ESRD), who received renal replacement therapy at the university affiliated dialysis program. Patients were grouped by initial dialysis modality as intent to treat. Four patients were on chronic hemodialysis (HD) and eight on peritoneal dialysis (PD). Six patients died, two on HD and four on PD. There were 451 deaths per 1000 patient years for patients on PD compared with 273 deaths per 1000 patients years for patients on HD (p < 0.0001), both significantly higher than the United States Renal Data System rate of 178 per 1000 patient years for patients with ESRD who were of similar age and race, p < 0.0001. The survival rate for patients on PD seemed to be worse, but that may be because unstable patients with failing heart transplants were directed toward PD. Efforts should be made to minimize nephrotoxicity after cardiac transplantation.

摘要

心脏移植的长期存活者因多年使用环孢素或他克莫司进行免疫抑制治疗而面临肾毒性风险。我们报告了12例在匹兹堡大学接受心脏移植,随后发展为终末期肾病(ESRD)并在大学附属透析项目接受肾脏替代治疗的患者。根据初始透析方式对患者进行分组作为意向性治疗。4例患者接受慢性血液透析(HD),8例接受腹膜透析(PD)。6例患者死亡,2例在HD组,4例在PD组。PD组患者每1000患者年有451例死亡,而HD组为每1000患者年273例死亡(p<0.0001),两者均显著高于美国肾脏数据系统中年龄和种族相似的ESRD患者每1000患者年178例的死亡率,p<0.0001。PD组患者的生存率似乎更差,但这可能是因为心脏移植失败的不稳定患者被导向了PD治疗。应努力将心脏移植后的肾毒性降至最低。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验